With a median follow-up of 44.5 months among survivors, OS was not significantly different between patients who received a TSR vs. 7 + 3 chemotherapy (31.8% vs. 44.4% at 1-year; P = 0.76), ponatinib vs. dasatinib (30% vs. 41.7% at 1-year; P = 0.59), or patients who presented with progressed vs. de novo CML-MBP (37.8% vs. 40% at 1-year; P = 0.62) (Fig. 1a and c). The gene discussed is MBP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.